3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Breast Neoplasms
63
Carcinoma, Non-Small-Cell Lung
60
Rectal Neoplasms
44
Glioblastoma
42
Stomach Neoplasms
37
Esophageal Neoplasms
33
Brain Neoplasms
33
Squamous Cell Carcinoma of Head and Neck
31
Colorectal Neoplasms
29
Pancreatic Neoplasms
26
Lung Neoplasms
24
Neoplasms
23
Glioma
23
Astrocytoma
22
Neoplasm Metastasis
21
Head and Neck Neoplasms
19
Sarcoma
17
Gliosarcoma
15
Esophageal Squamous Cell Carcinoma
15
Central Nervous System Neoplasms
15
Ovarian Neoplasms
14
Oligodendroglioma
13
Melanoma
13
Colonic Neoplasms
12
Adenocarcinoma Of Esophagus
12
Urinary Bladder Neoplasms
11
Prostatic Neoplasms
11
Carcinoma, Hepatocellular
11
Oropharyngeal Neoplasms
9
Carcinoma, Ovarian Epithelial
9
Interventions
lutetium Lu 177 dotatate
34
Everolimus
33
lanreotide
13
gallium Ga 68 dotatate
13
Temozolomide
13
Magnetic Resonance Spectroscopy
13
Nivolumab
12
pembrolizumab
11
Octreotide
11
Capecitabine
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
surufatinib
8
Sunitinib
8
Specimen Handling
7
Carboplatin
7
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Lutetium-177
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Bevacizumab
5
telotristat ethyl
4
olaparib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroendocrine Tumors
×
Surgical Procedures, Operative
×
Clear all
NCT03012789
2024-04-30
NETest_Sx
Wren Laboratories LLC
Phase NA
Active not recruiting
40 enrolled